General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings General discussions about mitochondrial diseases General discussions about genetic testing, diagnostics General discussions about accelerated approval pathway (AAP)
2026 · 3rd Quarter (July 1 - Sep 30)
MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.)
Filed by MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.).
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $120,000.00
- Filing UUID
- 62e746e4-6be4-4ea5-ad63-57c8dc472c49
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.